George John Alangaden

机构：Henry Ford Health · ORCID：0000-0001-8076-776X

发表论文 229 篇 · 总被引 8573 次 · h-index 45

代表论文

• Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial (2022 · The Lancet · 被引 185)
• The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 (2022 · Annals of Internal Medicine · 被引 63)
• Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir (2023 · Clinical Infectious Diseases · 被引 62)
• Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections (2022 · Open Forum Infectious Diseases · 被引 21)
• Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19 (2024 · Clinical Infectious Diseases · 被引 16)
• Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinic (2023 · Human Vaccines & Immunotherapeutics · 被引 13)